Document is current

Any future updates will be listed below

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

Crossref DOI link: https://doi.org/10.1186/bcr3735

Published Online: 2014-11-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark